AKBLF
Price
$22.05
Change
-$0.00 (-0.00%)
Updated
Dec 11 closing price
SMMT
Price
$16.98
Change
-$1.59 (-8.56%)
Updated
Dec 18, 04:59 PM (EDT)
85 days until earnings call
Ad is loading...

AKBLF vs SMMT

Header iconAKBLF vs SMMT Comparison
Open Charts AKBLF vs SMMTBanner chart's image
Alk Abello AS
Price$22.05
Change-$0.00 (-0.00%)
Volume$1
CapitalizationN/A
Summit Therapeutics
Price$16.98
Change-$1.59 (-8.56%)
Volume$53.28K
CapitalizationN/A
AKBLF vs SMMT Comparison Chart
Loading...
AKBLF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SMMT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
AKBLF vs. SMMT commentary
Dec 19, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is AKBLF is a Hold and SMMT is a Hold.

COMPARISON
Comparison
Dec 19, 2024
Stock price -- (AKBLF: $22.05 vs. SMMT: $18.57)
Brand notoriety: AKBLF and SMMT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: AKBLF: 1% vs. SMMT: 95%
Market capitalization -- AKBLF: $4.78B vs. SMMT: $13.69B
AKBLF [@Biotechnology] is valued at $4.78B. SMMT’s [@Biotechnology] market capitalization is $13.69B. The market cap for tickers in the [@Biotechnology] industry ranges from $482.1B to $0. The average market capitalization across the [@Biotechnology] industry is $2.67B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

AKBLF’s FA Score shows that 0 FA rating(s) are green whileSMMT’s FA Score has 2 green FA rating(s).

  • AKBLF’s FA Score: 0 green, 5 red.
  • SMMT’s FA Score: 2 green, 3 red.
According to our system of comparison, SMMT is a better buy in the long-term than AKBLF.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

AKBLF’s TA Score shows that 5 TA indicator(s) are bullish while SMMT’s TA Score has 4 bullish TA indicator(s).

  • AKBLF’s TA Score: 5 bullish, 1 bearish.
  • SMMT’s TA Score: 4 bullish, 3 bearish.
According to our system of comparison, AKBLF is a better buy in the short-term than SMMT.

Price Growth

AKBLF (@Biotechnology) experienced а 0.00% price change this week, while SMMT (@Biotechnology) price change was +3.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.67%. For the same industry, the average monthly price growth was -1.92%, and the average quarterly price growth was +0.65%.

Reported Earning Dates

SMMT is expected to report earnings on Mar 13, 2025.

Industries' Descriptions

@Biotechnology (-6.67% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SMMT($13.7B) has a higher market cap than AKBLF($4.78B). AKBLF has higher P/E ratio than SMMT: AKBLF (44.78) vs SMMT (26.36). SMMT YTD gains are higher at: 611.494 vs. AKBLF (66.415). AKBLF has higher annual earnings (EBITDA): 1.34B vs. SMMT (-183.16M). AKBLF has more cash in the bank: 556M vs. SMMT (487M). SMMT has less debt than AKBLF: SMMT (32.5M) vs AKBLF (510M). AKBLF has higher revenues than SMMT: AKBLF (5.38B) vs SMMT (0).
AKBLFSMMTAKBLF / SMMT
Capitalization4.78B13.7B35%
EBITDA1.34B-183.16M-733%
Gain YTD66.415611.49411%
P/E Ratio44.7826.36170%
Revenue5.38B0-
Total Cash556M487M114%
Total Debt510M32.5M1,569%
FUNDAMENTALS RATINGS
AKBLF vs SMMT: Fundamental Ratings
AKBLF
SMMT
OUTLOOK RATING
1..100
2969
VALUATION
overvalued / fair valued / undervalued
1..100
82
Overvalued
94
Overvalued
PROFIT vs RISK RATING
1..100
5227
SMR RATING
1..100
5298
PRICE GROWTH RATING
1..100
4835
P/E GROWTH RATING
1..100
837
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

AKBLF's Valuation (82) in the null industry is in the same range as SMMT (94) in the Biotechnology industry. This means that AKBLF’s stock grew similarly to SMMT’s over the last 12 months.

SMMT's Profit vs Risk Rating (27) in the Biotechnology industry is in the same range as AKBLF (52) in the null industry. This means that SMMT’s stock grew similarly to AKBLF’s over the last 12 months.

AKBLF's SMR Rating (52) in the null industry is somewhat better than the same rating for SMMT (98) in the Biotechnology industry. This means that AKBLF’s stock grew somewhat faster than SMMT’s over the last 12 months.

SMMT's Price Growth Rating (35) in the Biotechnology industry is in the same range as AKBLF (48) in the null industry. This means that SMMT’s stock grew similarly to AKBLF’s over the last 12 months.

SMMT's P/E Growth Rating (7) in the Biotechnology industry is significantly better than the same rating for AKBLF (83) in the null industry. This means that SMMT’s stock grew significantly faster than AKBLF’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
AKBLFSMMT
RSI
ODDS (%)
Bullish Trend 6 days ago
38%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
22%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
30%
Bullish Trend 2 days ago
84%
MACD
ODDS (%)
Bullish Trend 2 days ago
39%
Bullish Trend 2 days ago
83%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
28%
Bullish Trend 2 days ago
87%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
21%
Bearish Trend 2 days ago
82%
Advances
ODDS (%)
N/A
Bullish Trend 10 days ago
87%
Declines
ODDS (%)
N/A
Bearish Trend 6 days ago
79%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
33%
N/A
Aroon
ODDS (%)
Bearish Trend 2 days ago
22%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
AKBLF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SMMT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
ARECX14.37-0.04
-0.28%
AB Global Real Estate Investment C
VSPGX862.67-2.65
-0.31%
Vanguard S&P 500 Growth Index Instl
BREUX41.27-0.32
-0.77%
Baron Real Estate R6
HGXYX15.86-0.13
-0.81%
Hartford Global Impact Y
FCBSX35.51-0.34
-0.95%
Franklin Mutual U.S. Mid Cap Value C

AKBLF and

Correlation & Price change

A.I.dvisor tells us that AKBLF and MNPR have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that AKBLF and MNPR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To AKBLF
1D Price
Change %
AKBLF100%
N/A
MNPR - AKBLF
29%
Poorly correlated
+14.91%
MSCLF - AKBLF
27%
Poorly correlated
-11.72%
IOVA - AKBLF
26%
Poorly correlated
-0.38%
SMMT - AKBLF
25%
Poorly correlated
-0.59%
VBIZF - AKBLF
24%
Poorly correlated
N/A
More

SMMT and

Correlation & Price change

A.I.dvisor indicates that over the last year, SMMT has been closely correlated with BCDA. These tickers have moved in lockstep 70% of the time. This A.I.-generated data suggests there is a high statistical probability that if SMMT jumps, then BCDA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SMMT
1D Price
Change %
SMMT100%
-0.59%
BCDA - SMMT
70%
Closely correlated
+0.47%
VBIZF - SMMT
42%
Loosely correlated
N/A
DAWN - SMMT
32%
Poorly correlated
+0.16%
ERNA - SMMT
31%
Poorly correlated
-3.61%
IDYA - SMMT
30%
Poorly correlated
+1.07%
More